Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
AssigneeHealthquest Pharma Inc.
InventorsPeng Li, Wei Ye, Ke Ding, Xiaoyun Lu
Life of this patent
Estimating the term…
Abstract
This invention discloses use of (3-((1H-pyrazol[3,4-b]pyridine-5-substituted)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-substituted)methyl)-3-(trifluoromethyl)phenyl)benzamide) and a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating acute lymphoblastic leukemia in particular precursor B-cell lymphoblastic leukemia.
Claims3
A method of treating acute lymphocytic leukemia in a subject in need thereof comprising administering a therapeutically effective amount of (3-((1H-pyrazol[3,4-b]pyridine-5-substituted)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-substituted)methyl)-3-(trifluoromethyl)phenyl)benzamide) or a pharmaceutically acceptable salt thereof to the subject.
A method of treating precursor B-cell lymphocytic leukemia in a subject in need thereof comprising administering a therapeutically effective amount of (3-((1H-pyrazol[3,4-b]pyridine-5-substituted)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-substituted)methyl)-3-(trifluoromethyl)phenyl)benzamide) or a pharmaceutically acceptable salt thereof to the subject.
(canceled)
Dependencies are inferred from the claim text.